Edgewise Therapeutics files amended 8-K with unaudited pro forma financials for Servier asset sale

Edgewise Therapeutics filed an amended Form 8-K updating unaudited pro forma financials for the sale of its sevasemten program to Servier. The transaction closed on July 10, 2026, involving a $1.55 billion upfront payment. Pro forma results show a net cash increase of $1.5 billion and a 2025 pre-tax gain of $1.49 billion. Edgewise has repositioned as a cardiovascular-focused company.

Edgewise filed an amended Form 8-K to update unaudited pro forma financials tied to the sevasemten program sale to Servier. * Transaction closed July 10, 2026; consideration included USD 1.55 billion upfront cash, up to USD 1.1 billion in milestones excluded from pro forma. * Pro forma balance sheet as of March 31, 2026 reflected net cash increase of USD 1.5 billion, lifting cash to USD 1.53 billion. * Pro forma 2025 results included a USD 1.49 billion pre-tax gain; income tax expense of USD 259.84 million; net income of USD 1.14 billion. * Company repositioned as cardiovascular-focused, with pipeline centered on EDG-7500, EDG-15400, EDG-003. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Edgewise Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-084088), on July 16, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

Edgewise filed an amended Form 8-K to update unaudited pro forma financials tied to the sevasemten program sale to Servier. * Transaction closed July 10, 2026; consideration included USD 1.55 billion upfront cash, up to USD 1.1 billion in milestones excluded from pro forma. * Pro forma balance sheet as of March 31, 2026 reflected net cash increase of USD 1.5 billion, lifting cash to USD 1.53 billion. * Pro forma 2025 results included a USD 1.49 billion pre-tax gain; income tax expense of USD 259.84 million; net income of USD 1.14 billion. * Company repositioned as cardiovascular-focused, with pipeline centered on EDG-7500, EDG-15400, EDG-003. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Edgewise Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-084088), on July 16, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here